The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2005
year mood -0.10 · -0.20 to +0.00 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.25 -0.12 0 +0.12 +0.25 Jan Feb -0.20 Mar Apr May Jun Jul Aug Sep Oct Nov Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
-0.10-0.20-0.10-0.14-0.10-0.14-0.10-0.20-0.10+0.00+0.00+0.00

FDA COX-2 safety panel; industry-wide scrutiny

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 11, 2026
Top healthcare stories of 2005
Apr
FDA pulls Bextra, mandates black-box warnings on COX-2 painkillers baltimoresun.com →

The FDA forced Pfizer to withdraw Bextra due to cardiovascular and skin risks, requiring strong black-box warnings on all NSAIDs including Celebrex. The move leaves only Celebrex in the U.S. COX-2 market, impacting Pfizer's revenue and prompting broader scrutiny of post-market drug safety, while analysts expect continued debate over drug risk hierarchies and regulatory oversight.

Jun
Guidant recalls 50,000 defibrillators over short-circuit risk news.minnesota.publicradio.org →

Guidant Corp. recalled nearly 50,000 cardiac defibrillators due to a short-circuit flaw, linked to 45 malfunctions and two deaths, prompting FDA support and patient monitoring. The affected models include Prizm and Contak devices, with some eligible for reprogramming or replacement. The recall intensifies scrutiny on Guidant ahead of its $25.4 billion acquisition by Johnson & Johnson, potentially impacting regulatory approval and investor confidence.